Mark Mintun News Today

If approved, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind currently on the U.S. market after Leqembi from Biogen and Eisai.

People without memory problems could be diagnosed with Alzheimer's under a plan by an influential scientific panel dominated by members with ties to drug companies.

People without memory problems could be diagnosed with Alzheimer's under a plan by an influential scientific panel dominated by members with ties to drug companies.

New research shows another experimental Alzheimers drug can modestly slow patients inevitable worsening. Patients given monthly infusions of Eli Lilly and Co.s donanemab declined about four to seven months more

Older Black Americans have twice the rate of dementia as Whites

WASHINGTON - Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening - by about four to seven months, researchers reported Monday. Eli Lilly and Co. is seeking Food and ...

By Julie Steenhuysen NEW YORK (Reuters) - Groundbreaking treatments for Alzheimer's disease that work by removing a toxic protein called beta amyloid ...

Groundbreaking treatments for Alzheimer's disease that work by removing a toxic protein called beta amyloid from the brain may benefit whites more than Black Americans, whose disease may be driven by other factors, leading Alzheimer's experts told Reuters. The two drugs – Leqembi, from partner biotech firms Eisai and Biogen, and an experimental treatment developed by Eli Lilly, donanemab - are the first to offer real hope of slowing the fatal disease for the 6.5 million Am...

Researchers revealed that older Black Americans, who have twice the rate of dementia compared to whites were excluded from clinical trials of these drugs

Scientists say while these drugs may mark a new era in Alzheimers therapy, huge questions remain about which patients should try them and how much benefit theyll really notice.